Repligen (NASDAQ:RGEN) Earns Hold Rating from Analysts at Canaccord Genuity Group

Investment analysts at Canaccord Genuity Group initiated coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating and a $165.00 price target on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 2.54% from the stock’s previous close.

Several other analysts have also issued reports on the stock. Wolfe Research assumed coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $187.44.

Repligen Price Performance

Shares of RGEN opened at $160.92 on Tuesday. The firm has a market cap of $9.02 billion, a PE ratio of -434.92, a price-to-earnings-growth ratio of 4.64 and a beta of 0.96. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13. The business’s 50 day moving average price is $142.66 and its two-hundred day moving average price is $141.59. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same period in the previous year, the firm posted $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, equities analysts anticipate that Repligen will post 1.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RGEN. Champlain Investment Partners LLC increased its holdings in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares during the period. Bank of New York Mellon Corp boosted its position in Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares in the last quarter. Finally, DF Dent & Co. Inc. lifted its position in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.